Lehmann D F
Department of Medicine, University of Missouri, Kansas City.
Med Toxicol Adverse Drug Exp. 1987 Sep-Oct;2(5):383-7. doi: 10.1007/BF03259955.
Seven cases of crystalluria following primidone overdose have been reported since the 1950s. An eighth case of primidone crystalluria following overdose is presented. Because of low aqueous solubility (600 mg/L at 37 degrees C) which is directly proportional to temperature, any factor increasing renal excretion of unchanged primidone predisposes to crystal formation. Renal clearance is dependent on dosage because of negligible protein binding, zero-order conversion to phenobarbitone (phenobarbital) and first-order conversion to phenylethylmalonamide. Therapy with other anticonvulsants known to induce the metabolism to phenobarbitone does not appear to be protective against crystalluria in overdose situations. The critical serum primidone concentration for crystalluria presence seems to be 80 mg/L. There is evidence for nephrotoxicity of the crystals themselves if formed in vivo (actual crystal presence during voiding). The chemical phenomenon of supersaturation of a solution is protective against in vivo crystal formation with subsequent nephrotoxicity. Vigorous hydration to augment elimination and to lessen the propensity for renal toxicity is recommended.
自20世纪50年代以来,已报告了7例服用过量扑米酮后出现结晶尿的病例。本文介绍了第8例过量服用扑米酮后出现结晶尿的病例。由于其水溶性较低(37℃时为600mg/L),且与温度成正比,任何增加原形扑米酮肾排泄的因素都易导致晶体形成。由于蛋白结合可忽略不计、扑米酮零级转化为苯巴比妥以及一级转化为苯乙基丙二酰胺,肾清除率取决于剂量。已知可诱导代谢为苯巴比妥的其他抗惊厥药物治疗似乎并不能预防过量情况下的结晶尿。出现结晶尿时扑米酮的临界血清浓度似乎为80mg/L。有证据表明,如果晶体在体内形成(排尿时实际存在晶体),晶体会对肾脏产生毒性。溶液过饱和的化学现象可防止体内晶体形成及随后的肾毒性。建议积极补液以促进排泄并降低肾毒性倾向。